GO:0005018 platelet-derived growth factor alpha-receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005018 describes the molecular function of binding PDGF-AA, PDGF-BB or PDGF-AB to initiate intracellular signaling.
• The primary gene encoding this activity is PDGFRA, a receptor tyrosine kinase that is essential for fibroblast survival and cardiac development.
• PDGFRA signaling regulates mechano-responsiveness in lung fibroblasts through RAC1 and controls fetal testis differentiation via an ERK-CREB axis.
• Dysregulated PDGFRA activity is implicated in prostate cancer skeletal metastasis and is required for human cytomegalovirus infection.
• PDGFRA-positive cells mediate purinergic inhibitory nerve-smooth muscle transmission and contribute to myofascial trigger point pain.
• Avapritinib, a PDGFRA inhibitor, has been approved for gastrointestinal stromal tumors, validating the receptor as a therapeutic target.
Description
Platelet-derived growth factor alpha-receptor activity (GO:0005018) is a molecular function defined as the binding of platelet-derived growth factor isoforms PDGF-AA, PDGF-BB or PDGF-AB to initiate a change in cell activity. This activity is mediated by the PDGFRA gene product, a receptor tyrosine kinase that plays critical roles in embryonic development, tissue homeostasis, and disease pathogenesis. Researchers study this term to understand how extracellular growth factor signals are transduced into cellular responses such as proliferation, migration, and survival. The receptor is essential for cardiac fibroblast survival, as genetic deletion of Pdgfra leads to increased apoptosis and impaired heart function. In lung fibroblasts, PDGFRA cooperates with RAC1 to regulate mechano-responsiveness, linking mechanical cues to fibrotic responses. Beyond normal physiology, PDGFRA activity is hijacked in various pathologies, including prostate cancer skeletal metastasis and human cytomegalovirus infection. Understanding the molecular mechanisms, regulatory networks, and disease associations of GO:0005018 is therefore crucial for developing targeted therapies. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of platelet-derived growth factor alpha-receptor activity, its key genes, research models, and therapeutic implications.
platelet-derived growth factor alpha-receptor activity At A Glance
| GO ID | GO:0005018 |
|---|---|
| GO term | platelet-derived growth factor alpha-receptor activity |
| Ontology | molecular_function |
| Synonym | alphaPDGF receptor activity, PDGF alpha-receptor activity |
| Major function | Binding PDGF-AA, PDGF-BB or PDGF-AB to initiate intracellular signaling |
| Primary gene | PDGFRA |
| Cellular location | Plasma membrane |
| Pathway | Receptor tyrosine kinase signaling |
| Disease relevance | Cancer, fibrosis, viral infection, developmental disorders |
What Is GO:0005018?
Platelet-derived growth factor alpha-receptor activity (GO:0005018) is the molecular function of combining with platelet-derived growth factor isoforms PDGF-AA, PDGF-BB or PDGF-AB to initiate a change in cell activity. This activity is intrinsic to the PDGFRA protein, a cell-surface receptor tyrosine kinase that dimerizes upon ligand binding and autophosphorylates to trigger downstream signaling cascades.
Why Is platelet-derived growth factor alpha-receptor activity Important in Cell Biology?
Platelet-derived growth factor alpha-receptor activity is fundamental to numerous physiological and pathological processes. It governs embryonic development, particularly cardiac fibroblast survival and fetal testis differentiation. In adult tissues, it regulates mechano-responsiveness in lung fibroblasts, contributing to fibrosis when dysregulated. The receptor is also exploited by pathogens such as human cytomegalovirus to facilitate infection. Moreover, PDGFRA activity is implicated in cancer progression, including prostate cancer skeletal metastasis, and in pain signaling within myofascial trigger points. The clinical approval of avapritinib, a PDGFRA inhibitor, underscores the therapeutic importance of targeting this activity. Thus, understanding GO:0005018 is essential for both basic developmental biology and translational medicine.
• Essential for cardiac fibroblast survival and heart development.
• Regulates mechano-responsiveness in lung fibroblasts via RAC1.
• Controls fetal testis differentiation through an ERK-CREB axis.
• Required for human cytomegalovirus infection.
• Implicated in prostate cancer skeletal metastasis.
• Mediates purinergic inhibitory nerve-smooth muscle transmission.
• Contributes to myofascial trigger point pain and contraction knots.
• Targeted by approved drug avapritinib for gastrointestinal stromal tumors.
• Plays a role in tissue fibrosis and wound healing.
• Serves as a model for receptor tyrosine kinase signaling research.
What Happens During platelet-derived growth factor alpha-receptor activity?
Ligand Binding and Receptor Dimerization
In simple terms: Growth factor molecules bind to the receptor on the cell surface, causing two receptors to pair up.
Platelet-derived growth factor isoforms PDGF-AA, PDGF-BB or PDGF-AB bind to the extracellular domain of PDGFRA, inducing receptor dimerization. This binding event is the initiating step of GO:0005018 and is required for subsequent activation of the receptor's intrinsic tyrosine kinase activity. The specificity of ligand binding determines downstream signaling outcomes in different cell types.
Autophosphorylation and Kinase Activation
In simple terms: The paired receptors add phosphate groups to each other, turning on their signaling ability.
Upon dimerization, PDGFRA undergoes autophosphorylation on specific tyrosine residues within its intracellular kinase domain. This autophosphorylation creates docking sites for SH2-domain-containing proteins and fully activates the receptor's kinase activity, enabling it to phosphorylate downstream substrates. This step is critical for transmitting the signal from the cell surface to intracellular pathways.
Downstream Signaling Cascades
In simple terms: The activated receptor triggers a chain of molecular signals inside the cell.
Activated PDGFRA phosphorylates adaptor proteins such as GAB1 and PLCγ, leading to activation of the ERK-MAPK, PI3K-AKT, and other signaling pathways. In fetal testis differentiation, PDGFRA signals through an ERK-CREB axis to regulate gene expression. In lung fibroblasts, PDGFRA cooperates with RAC1 to mediate mechano-responsiveness. These cascades ultimately drive changes in cell proliferation, migration, survival, and gene expression.
Cellular Responses and Feedback Regulation
In simple terms: The signal leads to cell actions and is eventually turned off.
Downstream signaling from GO:0005018 results in diverse cellular responses, including fibroblast survival, smooth muscle contraction, and inflammatory pain signaling. The activity is tightly regulated by negative feedback mechanisms, including receptor internalization, degradation, and dephosphorylation by phosphatases. Dysregulation of these feedback loops can lead to sustained signaling, contributing to diseases such as cancer and fibrosis.
Key Genes Involved in GO:0005018 platelet-derived growth factor alpha-receptor activity
The following genes and proteins are directly involved in or regulate platelet-derived growth factor alpha-receptor activity (GO:0005018).
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDGFRA | Encodes the alpha-receptor tyrosine kinase that binds PDGF-AA, -BB, -AB | Central to GO:0005018; knockout causes cardiac defects |
| PDGFB | Ligand for PDGFRA; forms PDGF-BB and PDGF-AB | Activates receptor in fibrosis and cancer |
| PDGFA | Ligand for PDGFRA; forms PDGF-AA | Regulates developmental signaling |
| RAC1 | Small GTPase mediating mechano-responsiveness downstream of PDGFRA | Modulates lung fibroblast function |
| ERK1/2 | MAP kinases downstream of PDGFRA | Transmit signals to CREB in testis differentiation |
| CREB | Transcription factor activated by ERK downstream of PDGFRA | Regulates gene expression in fetal testis |
| GAB1 | Adaptor protein docking to phosphorylated PDGFRA | Links receptor to PI3K-AKT pathway |
| PLCγ | Phospholipase C gamma activated by PDGFRA | Produces second messengers for signaling |
| PI3K | Lipid kinase activated by PDGFRA | Promotes cell survival and proliferation |
| AKT | Serine/threonine kinase downstream of PI3K | Mediates survival signals |
| SRC | Non-receptor tyrosine kinase interacting with PDGFRA | Modulates receptor signaling |
| STAT3 | Transcription factor activated by PDGFRA | Regulates gene expression in cancer |
| PTPN11 | Protein tyrosine phosphatase SHP2 | Negatively regulates PDGFRA signaling |
| CBL | E3 ubiquitin ligase targeting activated PDGFRA | Controls receptor degradation |
| HCMV gB | Human cytomegalovirus glycoprotein binding PDGFRA | Required for viral entry |
| PDGFRB | Beta-receptor that heterodimerizes with PDGFRA | Modulates ligand specificity |
| NCAM | Neural cell adhesion molecule interacting with PDGFRA | Modulates signaling in nerve-smooth muscle transmission |
| TRPV1 | Ion channel in pain signaling downstream of PDGFRA | Mediates inflammatory pain in trigger points |
How Is platelet-derived growth factor alpha-receptor activity Regulated?
Platelet-derived growth factor alpha-receptor activity is regulated at multiple levels. Ligand availability controls receptor activation, with PDGF-AA, PDGF-BB, and PDGF-AB exhibiting different affinities and signaling potencies. Receptor internalization and degradation, mediated by CBL ubiquitination, terminate signaling. Phosphatases such as PTPN11 dephosphorylate the receptor to attenuate kinase activity. Additionally, mechanical cues in the extracellular matrix modulate PDGFRA signaling through RAC1 in lung fibroblasts. In fetal testis, ERK-CREB axis downstream of PDGFRA is tightly regulated to ensure proper differentiation. Dysregulation of these mechanisms can lead to pathological conditions such as cancer and fibrosis.
platelet-derived growth factor alpha-receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDGFRA | Prostate cancer skeletal metastasis | PDGFRA knockout prostate cancer cell lines |
| PDGFRA | Gastrointestinal stromal tumor | Patient-derived xenografts with PDGFRA mutations |
| PDGFRA | Cardiac fibrosis and heart failure | Cardiac fibroblast-specific Pdgfra knockout mice |
| PDGFRA | Human cytomegalovirus infection | PDGFRA knockout cells challenged with HCMV |
| PDGFRA | Myofascial trigger point pain | Rat model with PDGFRA inhibitor treatment |
PDGFRA in Cancer and Metastasis
Dysregulated platelet-derived growth factor alpha-receptor activity contributes to cancer progression. In prostate cancer, PDGFRA signaling promotes skeletal metastasis, and inhibition of this pathway reduces metastatic burden in preclinical models. The receptor is also implicated in gastrointestinal stromal tumors, where activating mutations in PDGFRA drive tumor growth; the inhibitor avapritinib has been approved for this indication. These findings highlight GO:0005018 as a therapeutic target in oncology.
PDGFRA in Fibrosis and Tissue Remodeling
PDGFRA activity is essential for cardiac fibroblast survival, and its loss leads to increased apoptosis and impaired cardiac function. In lung fibroblasts, PDGFRA cooperates with RAC1 to regulate mechano-responsiveness, a process that contributes to pulmonary fibrosis when aberrant. Targeting PDGFRA signaling may therefore offer therapeutic benefits in fibrotic diseases.
PDGFRA in Infectious Disease
Human cytomegalovirus (HCMV) exploits PDGFRA as a receptor for viral entry. PDGFRA activation is required for HCMV infection, and blocking this interaction inhibits viral entry. This positions GO:0005018 as a potential antiviral target.
PDGFRA in Pain and Neuromuscular Transmission
PDGFRA-positive cells mediate purinergic inhibitory nerve-smooth muscle transmission, influencing smooth muscle contractility. In a rat model of myofascial trigger points, PDGFRA signaling induces contraction knots and inflammatory pain-like behavior, suggesting a role in musculoskeletal pain.
From platelet-derived growth factor alpha-receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDGFRA loss affect cardiac fibroblast survival? | Pdgfra knockout mice |
| How does PDGFRA regulate mechano-responsiveness in lung fibroblasts? | RAC1 knockout lung fibroblasts |
| What is the role of PDGFRA in fetal testis differentiation? | Pdgfra knockout mouse embryos |
| Can PDGFRA inhibition block HCMV infection? | PDGFRA knockout human fibroblasts |
| Does PDGFRA signaling contribute to cancer metastasis? | PDGFRA knockdown prostate cancer cells |
| What is the effect of PDGFRA activation on pain behavior? | Rat myofascial trigger point model |
How to Study the platelet-derived growth factor alpha-receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of PDGFRA function | Cardiac fibroblast survival studies |
| Phospho-Western blot | Receptor autophosphorylation and downstream kinase activity | Ligand stimulation assays |
| Co-immunoprecipitation | Receptor dimerization and protein interactions | Mechanistic studies |
| Surface plasmon resonance | Ligand binding affinity | PDGF isoform specificity |
| RNA-seq | Transcriptional changes downstream of PDGFRA | Fetal testis differentiation |
| Pharmacological inhibition | Acute blockade of kinase activity | Therapeutic validation |
| Immunofluorescence | Subcellular localization of PDGFRA | Tissue distribution studies |
| Animal models | In vivo function of PDGFRA | Pain and metastasis research |
Genetic Knockout and Knockdown
CRISPR-Cas9-mediated knockout of PDGFRA in cell lines and animal models is a powerful approach to study GO:0005018. For example, Pdgfra knockout mice revealed essential roles in cardiac fibroblast survival and fetal testis differentiation. RNA interference can also be used for transient knockdown to assess acute effects on signaling.
Pharmacological Inhibition
Small molecule inhibitors such as avapritinib selectively target PDGFRA kinase activity. These inhibitors are valuable for probing the acute effects of receptor inhibition on downstream signaling and cellular phenotypes, and for validating therapeutic potential in disease models.
Phosphoproteomics and Signaling Assays
Mass spectrometry-based phosphoproteomics can identify autophosphorylation sites on PDGFRA and downstream substrates upon ligand stimulation. Western blotting with phospho-specific antibodies against PDGFRA, ERK, AKT, and CREB is commonly used to monitor pathway activation.
Ligand Binding and Receptor Dimerization Assays
Surface plasmon resonance and co-immunoprecipitation can measure PDGF-AA, -BB, or -AB binding to PDGFRA and subsequent receptor dimerization. These methods help quantify the affinity and specificity of ligand-receptor interactions central to GO:0005018.
How CRISPR Can Be Used to Study GO:0005018 platelet-derived growth factor alpha-receptor activity
Knockout
CRISPR-Cas9 knockout of PDGFRA is used to completely abolish platelet-derived growth factor alpha-receptor activity. This approach has demonstrated essential roles in cardiac fibroblast survival, where Pdgfra deletion leads to increased apoptosis, and in fetal testis differentiation, where knockout impairs ERK-CREB signaling. Knockout models are also valuable for studying HCMV infection, as PDGFRA-null cells resist viral entry.
Point Mutation
Point mutations in PDGFRA, such as kinase domain mutations found in gastrointestinal stromal tumors, can be introduced using CRISPR base editing or homology-directed repair. These models help dissect the contribution of specific residues to receptor activation and drug sensitivity, informing the development of targeted inhibitors like avapritinib.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous PDGFRA locus enables real-time tracking of receptor expression, localization, and dynamics. Tagged knock-in models are useful for studying receptor trafficking and interactions under physiological conditions.
Overexpression
Overexpression of wild-type or mutant PDGFRA via CRISPR activation or lentiviral delivery can amplify receptor signaling to study downstream effects. This approach is particularly useful for modeling PDGFRA-driven cancers and for screening potential therapeutic compounds.
How EDITGENE Supports platelet-derived growth factor alpha-receptor activity Research
Researchers studying platelet-derived growth factor alpha-receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for platelet-derived growth factor alpha-receptor activity research.
Frequently Asked Questions About platelet-derived growth factor alpha-receptor activity
What is platelet-derived growth factor alpha-receptor activity?
It is the molecular function defined by GO:0005018, where the PDGFRA receptor binds PDGF-AA, PDGF-BB or PDGF-AB to initiate intracellular signaling.
What genes are involved in platelet-derived growth factor alpha-receptor activity?
The primary gene is PDGFRA, which encodes the alpha-receptor. Ligands include PDGFA and PDGFB, and downstream effectors include RAC1, ERK, and CREB.
What diseases are associated with PDGFRA activity?
PDGFRA activity is implicated in prostate cancer metastasis, gastrointestinal stromal tumors, cardiac fibrosis, and human cytomegalovirus infection.
How is platelet-derived growth factor alpha-receptor activity regulated?
It is regulated by ligand availability, receptor internalization, phosphatases like PTPN11, and mechanical cues via RAC1.
What is the role of PDGFRA in cardiac fibroblasts?
PDGFRA is essential for cardiac fibroblast survival; its deletion leads to increased apoptosis and impaired heart function.
Can PDGFRA be targeted for cancer therapy?
Yes, the inhibitor avapritinib targets PDGFRA and has been approved for gastrointestinal stromal tumors.
How does PDGFRA contribute to viral infection?
Human cytomegalovirus requires PDGFRA activation for entry into cells, making it a potential antiviral target.
What research models are used to study PDGFRA?
Common models include Pdgfra knockout mice, CRISPR knockout cell lines, and pharmacological inhibitors like avapritinib.
What is the role of PDGFRA in pain?
PDGFRA signaling induces contraction knots and inflammatory pain-like behavior in a rat model of myofascial trigger points.
How can CRISPR be used to study PDGFRA?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to dissect PDGFRA function in health and disease.
Conclusion
Platelet-derived growth factor alpha-receptor activity (GO:0005018) is a critical molecular function mediated by the PDGFRA receptor tyrosine kinase. It governs diverse physiological processes, from cardiac fibroblast survival to fetal testis differentiation, and is dysregulated in cancer, fibrosis, and infectious diseases. The availability of CRISPR models, pharmacological inhibitors, and advanced bioinformatics tools makes it an attractive target for both basic research and therapeutic development. EDITGENE's comprehensive services empower researchers to unravel the complexities of this pathway and translate findings into clinical applications.
References
- 1. Ivey MJ et al.. 2019. Platelet-derived growth factor receptor-α is essential for cardiac fibroblast survival.. Am J Physiol Heart Circ Physiol 317(2):H330-H344 PMID: 31125253
- 2. Liu Q et al.. 2011. Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.. Chin J Cancer 30(9):612-9 PMID: 21880182
- 3. Huang X et al.. 2020. [Role of platelet-derived growth factor receptor α positive cells in purinergic inhibitory nerve-smooth muscle transmission].. Sheng Li Xue Bao 72(3):391-398 PMID: 32572436
- 4. Liu Y et al.. 2024. Platelet-derived Growth Factor Receptor-α Induces Contraction Knots and Inflammatory Pain-like Behavior in a Rat Model of Myofascial Trigger Points.. Anesthesiology 141(5):929-945 PMID: 39058323
- 5. McGowan SE et al.. 2017. Platelet-derived growth factor receptor-α and Ras-related C3 botulinum toxin substrate-1 regulate mechano-responsiveness of lung fibroblasts.. Am J Physiol Lung Cell Mol Physiol 313(6):L1174-L1187 PMID: 28775097
- 6. Dhillon S. 2020. Avapritinib: First Approval.. Drugs 80(4):433-439 PMID: 32100250
- 7. Li SY et al.. 2026. Platelet-derived growth factor receptor alpha regulates fetal testis differentiation via an ERK-CREB axis.. Proc Natl Acad Sci U S A 123(4):e2515138123 PMID: 41564132
- 8. Soroceanu L et al.. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection.. Nature 455(7211):391-5 PMID: 18701889
